Our findings reveal that 25.6% of TCGA colorectal cancer (CRC) tumors exhibit BRAF pathway activation, even in 19.4% of BRAF wild-type (WT) cases, suggesting alternative mechanisms driving pathway activation. The gene discussed is BRAF; the disease is colorectal carcinoma.